Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies

Stock Information for Immunome Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Immunome Inc.

Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Immunome Appoints Carol A. Schafer to Board of Directors
Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
Immunome to Acquire Antibody-Related Assets and Materials from Atreca
Immunome to Present at the Stifel 2023 Healthcare Conference
Immunome Reports Third Quarter 2023 Financial Results
Immunome Appoints Jean-Jacques Bienaimé to Board of Directors
Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.